BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24977385)

  • 1. Epidemiology of HPV infection and current status of cervical cancer prevention in Greece: final results of the LYSISTRATA cross-sectional study.
    Agorastos T; Chatzistamatiou K; Zafrakas M; Siamanta V; Katsamagkas T; Constantinidis TC; Lampropoulos AF;
    Eur J Cancer Prev; 2014 Sep; 23(5):425-31. PubMed ID: 24977385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
    Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
    Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
    de Sanjose S; Quint WG; Alemany L; Geraets DT; Klaustermeier JE; Lloveras B; Tous S; Felix A; Bravo LE; Shin HR; Vallejos CS; de Ruiz PA; Lima MA; Guimera N; Clavero O; Alejo M; Llombart-Bosch A; Cheng-Yang C; Tatti SA; Kasamatsu E; Iljazovic E; Odida M; Prado R; Seoud M; Grce M; Usubutun A; Jain A; Suarez GA; Lombardi LE; Banjo A; Menéndez C; Domingo EJ; Velasco J; Nessa A; Chichareon SC; Qiao YL; Lerma E; Garland SM; Sasagawa T; Ferrera A; Hammouda D; Mariani L; Pelayo A; Steiner I; Oliva E; Meijer CJ; Al-Jassar WF; Cruz E; Wright TC; Puras A; Llave CL; Tzardi M; Agorastos T; Garcia-Barriola V; Clavel C; Ordi J; Andújar M; Castellsagué X; Sánchez GI; Nowakowski AM; Bornstein J; Muñoz N; Bosch FX;
    Lancet Oncol; 2010 Nov; 11(11):1048-56. PubMed ID: 20952254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledge, attitudes, and practices toward cervical cancer prevention among women in Kampong Speu Province, Cambodia.
    Touch S; Oh JK
    BMC Cancer; 2018 Mar; 18(1):294. PubMed ID: 29544466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pap test compliance and cervical cancer screening intervals on human papillomavirus vaccine acceptance.
    Ferris DG; Waller J; Dickinson A; McCracken C; Goebel A
    J Low Genit Tract Dis; 2012 Jan; 16(1):39-44. PubMed ID: 22126831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
    Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
    Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
    Konno R; Shin HR; Kim YT; Song YS; Sasagawa T; Inoue M; Park JS
    Vaccine; 2008 Aug; 26 Suppl 12():M30-42. PubMed ID: 18945412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus: science and technologies for the elimination of cervical cancer.
    Bosch FX
    Expert Opin Pharmacother; 2011 Oct; 12(14):2189-204. PubMed ID: 21756205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of abnormal cervical smears in a hospital cohort of French women beyond the upper age limit screening program.
    Luquain A; Belglaiaa E; Guenat D; Vrecko S; Riethmuller D; Valmary-Degano S; Bedgedjian I; Chouham S; Prétet JL; Mougin C
    Prev Med; 2015 Dec; 81():157-62. PubMed ID: 26348451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified laboratory.
    Zheng B; Li Z; Griffith CC; Yan S; Chen C; Ding X; Liang X; Yang H; Zhao C
    Cancer Cytopathol; 2015 Jul; 123(7):428-34. PubMed ID: 25954852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus prevalence and type distribution in 3603 HIV-positive and HIV-negative women in the general population of Tanzania: the PROTECT study.
    Dartell M; Rasch V; Kahesa C; Mwaiselage J; Ngoma T; Junge J; Gernow A; Ejlersen SF; Munk C; Iftner T; Kjaer SK
    Sex Transm Dis; 2012 Mar; 39(3):201-8. PubMed ID: 22337107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests.
    Zhao C; Elishaev E; Yuan KH; Yu J; Austin RM
    Cancer; 2007 Oct; 111(5):292-7. PubMed ID: 17879368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
    Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knowledge, attitudes, practice on human papilloma virus and cervical cancer among Trinidadian women.
    Chekuri A; Bassaw B; Affan AM; Habet G; Mungrue K
    J Obstet Gynaecol; 2012 Oct; 32(7):691-4. PubMed ID: 22943720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program.
    Tabrizi SN; Brotherton JM; Stevens MP; Condon JR; McIntyre P; Smith D; Garland SM;
    J Clin Virol; 2014 Jul; 60(3):250-6. PubMed ID: 24854516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up.
    Branca M; Garbuglia AR; Benedetto A; Cappiello T; Leoncini L; Migliore G; Agarossi A; Syrjänen K;
    Int J STD AIDS; 2003 Jun; 14(6):417-25. PubMed ID: 12816671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge and attitude of Uyghur women in Xinjiang province of China related to the prevention and early detection of cervical cancer.
    Abudukadeer A; Azam S; Mutailipu AZ; Qun L; Guilin G; Mijiti S
    World J Surg Oncol; 2015 Mar; 13():110. PubMed ID: 25885660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study.
    Iftner T; Eberle S; Iftner A; Holz B; Banik N; Quint W; Straube AN
    J Med Virol; 2010 Nov; 82(11):1928-39. PubMed ID: 20872721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.